SG11201904535VA - Prevention and treatment of bone and cartilage damage or disease - Google Patents

Prevention and treatment of bone and cartilage damage or disease

Info

Publication number
SG11201904535VA
SG11201904535VA SG11201904535VA SG11201904535VA SG11201904535VA SG 11201904535V A SG11201904535V A SG 11201904535VA SG 11201904535V A SG11201904535V A SG 11201904535VA SG 11201904535V A SG11201904535V A SG 11201904535VA SG 11201904535V A SG11201904535V A SG 11201904535VA
Authority
SG
Singapore
Prior art keywords
international
bone
prevention
treatment
negative control
Prior art date
Application number
SG11201904535VA
Inventor
Åkerlund Evy Lundgren
Christina Uvebrant
Jan Talts
Original Assignee
Xintela Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xintela Ab filed Critical Xintela Ab
Publication of SG11201904535VA publication Critical patent/SG11201904535VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction

Abstract

International Patent Classification: A61K 35/28 (2015.01) A61P 19/00 (2006.01) A61L 27/38 (2006.01) A61P 19/02 (2006.01) C12N 5/0775 (2010.01) A61P 19/08 (2006.01) (21) International Application Number: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) WIP0 I PCT omit °nolo oil! oil 111m011OII1111101 ow (10) International Publication Number WO 2018/138322 Al PCT/EP2018/052104 (22) International Filing Date: 29 January 2018 (29.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/451,372 27 January 2017 (27.01.2017) US (71) Applicant: XINTELA AB [SE/SE]; Medicon Village, 223 81 Lund (SE). (72) Inventors: LUNDGREN AKERLUND, Evy; Trollsjova- gen 165, 237 33 Bjarred (SE). UVEBRANT, Christina; Karleksgatan 4, 21 145 Malmo (SE). TALTS, Jan; Sarslovs Byavag 31, 245 93 Staffanstorp (SE). (74) Agent: HOIBERG P/S; Adelgade 12, 1304 Copenhagen K (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) (54) Title: PREVENTION AND TREATMENT OF BONE AND CARTILAGE DAMAGE OR DISEASE (57) : Compositions and methods for the prevention and/or treatment BM AT Negative control Antibody-labeled cells of conditions involving disease or damage in mammalian cartilage and bone, 1100 Igo° 5 using mesenchymal stem cells isolated with anti-integrin a10 antibodies are 1500 disclosed. CD44 3 500 ZS B50 '- Negative control C ° D45 51) U Antibody-labeled cells 850- r - 800 1400 200 1-1 f\"1 N CD90 11 00 11 O N C 0 T2 g Negative control Antibody-labeled cells 1200 -4-2 T -T \" - C --/ 1500 1000 Figure 1
SG11201904535VA 2017-01-27 2018-01-29 Prevention and treatment of bone and cartilage damage or disease SG11201904535VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451372P 2017-01-27 2017-01-27
PCT/EP2018/052104 WO2018138322A1 (en) 2017-01-27 2018-01-29 Prevention and treatment of bone and cartilage damage or disease

Publications (1)

Publication Number Publication Date
SG11201904535VA true SG11201904535VA (en) 2019-08-27

Family

ID=61168072

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201904535VA SG11201904535VA (en) 2017-01-27 2018-01-29 Prevention and treatment of bone and cartilage damage or disease

Country Status (17)

Country Link
US (2) US11517593B2 (en)
EP (2) EP3919064A1 (en)
JP (1) JP7210829B2 (en)
KR (1) KR102580320B1 (en)
CN (1) CN110234329A (en)
AU (1) AU2018211504B2 (en)
BR (1) BR112019013508A2 (en)
CA (1) CA3050099C (en)
DK (1) DK3573630T3 (en)
ES (1) ES2870776T3 (en)
IL (1) IL266772B (en)
LT (1) LT3573630T (en)
MX (1) MX2019008872A (en)
PL (1) PL3573630T3 (en)
PT (1) PT3573630T (en)
SG (1) SG11201904535VA (en)
WO (1) WO2018138322A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066569A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
KR20200118151A (en) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for delivery of therapeutic proteins
WO2021092199A1 (en) * 2019-11-08 2021-05-14 Kansas State University Research Foundation Isolation, preservation, and expansion of canine umbilical cord mesenchymal stromal cells
CN112941021A (en) * 2020-03-13 2021-06-11 深圳市第二人民医院(深圳市转化医学研究院) Culture method of osteoarthritis joint fluid-derived mesenchymal stem cells
KR20230008159A (en) 2020-05-07 2023-01-13 신텔라 에이비 Stem Cells for Treatment of Respiratory Disorders
CN113667635A (en) * 2020-05-14 2021-11-19 梦芊科技知识产权有限公司 Xeno-free medium and method for amplifying mesenchymal stem cells using the same
CN112430269B (en) * 2021-01-28 2021-04-20 中赛干细胞基因工程有限公司 Composition for promoting osteogenic differentiation of umbilical cord blood stem cells and application thereof
KR20240021178A (en) 2021-05-20 2024-02-16 신텔라 에이비 Mesenchymal stem cells for use in the treatment of skin defects
CN114540298A (en) * 2022-03-25 2022-05-27 北京瑷格干细胞科技有限公司 Stem cell serum-free medium and preparation method thereof
CN115651076B (en) * 2022-12-09 2023-09-29 北京大学口腔医学院 Surface marker of human bone marrow mesenchymal stem cell-derived apoptosis vesicle and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405345C (en) * 2000-04-25 2012-09-18 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
EP1513877B1 (en) 2002-06-14 2008-01-16 Cartela AB Marker for stem cells and its use
SE0301087D0 (en) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
EP1996698A1 (en) * 2006-03-01 2008-12-03 Cartela R&D AB Expansion and differentiation of mesenchymal stem cells
WO2008072000A2 (en) 2006-12-15 2008-06-19 Xintela Ab (Se) Use of integrin alpha 10 binding antibody to modulate extracellular matrix ( cartilage) turnover
CA2693827A1 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes

Also Published As

Publication number Publication date
DK3573630T3 (en) 2021-06-07
KR102580320B1 (en) 2023-09-19
BR112019013508A2 (en) 2020-01-07
CN110234329A (en) 2019-09-13
AU2018211504B2 (en) 2022-08-18
EP3919064A1 (en) 2021-12-08
IL266772A (en) 2019-07-31
US20230128397A1 (en) 2023-04-27
LT3573630T (en) 2021-05-25
CA3050099A1 (en) 2018-08-02
EP3573630B1 (en) 2021-03-17
US20200038449A1 (en) 2020-02-06
KR20190107686A (en) 2019-09-20
JP7210829B2 (en) 2023-01-24
US11517593B2 (en) 2022-12-06
WO2018138322A1 (en) 2018-08-02
JP2020505916A (en) 2020-02-27
PL3573630T3 (en) 2021-09-13
CA3050099C (en) 2024-04-16
PT3573630T (en) 2021-05-06
ES2870776T3 (en) 2021-10-27
MX2019008872A (en) 2019-09-18
IL266772B (en) 2022-04-01
EP3573630A1 (en) 2019-12-04
AU2018211504A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201907857RA (en) Edible and biodegradable utensils
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201901594RA (en) Cell suspension for use in the treatment of lower extremity peripheral artery disease
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201805001UA (en) Method of treating influenza a
SG11201900058YA (en) Method of generating mesenchymal stem cells and uses thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201909041SA (en) Anti-pd-l1 antibody and use thereof
SG11201407812SA (en) Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
SG11201805170XA (en) Cellular glycosaminoglycan compositions and methods of making and using
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201900361RA (en) Methods of treating prostate cancer
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900043TA (en) Antibody formulations
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease